# US 2023/0265197 A1 · Monoclonal antibodies against her2 epitope and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265197 A1
- Document ID: US20230265197A1
- Status: Published application
- Kind: A1
- Application number: 18/049,793
- Filed: 2022-10-26
- Published: 2023-08-24
- Earliest claimed: 2014-06-18
- Assignees: Mersana Therapeutics, Inc.
- Applicants: Mersana Therapeutics, Inc.
- Inventors: Natalya D. BODYAK; Michael J. DEVIT; Eric M. KRAULAND; Timothy B. LOWINGER; Peter U. PARK; Bianka PRINZ; Aleksandr V. YURKOVETSKIY
- Web page: https://patentgrep.com/patent/US20230265197A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6883: {Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.

## Claims

### Claim 1

A method of identifying an antibody or antigen binding fragment thereof that binds a human HER2 receptor at a defined epitope comprising:
a) contacting an immobilized Her-2 receptor polypeptide with:
i) a first antibody or antigen binding fragment thereof comprising a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence FTFSSYSMN (SEQ ID NO: 25); a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence YISSSSSTIYYADSVKG (SEQ ID NO: 26); a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GGHGYFDL (SEQ ID NO: 27) and a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence RASQSVSSSYLA (SEQ ID NO: 28); a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GASSRAT (SEQ ID NO: 21); and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYHHSPLT (SEQ ID NO: 29) to a solid substrate; and
ii) a second antibody or antigen binding fragment thereof
(b) determining whether the second antibody competes for binding to HER2 receptor with the first antibody;
wherein when the second antibody competes for binding to HER2 receptor with the first antibody indicates that the second antibody binds the human HER2 receptor at a defined epitope.

### Claim 2 (depends on 1)

The method of claim 1, wherein either the first or second antibody or antigen binding fragment thereof is labeled.

### Claim 3 (depends on 2)

The method of claim 2, wherein the label is a detectable fluorescent or radioactive marker.

### Claim 4 (depends on 1)

The method of claim 1, wherein the immobilized HER2 receptor polypeptide is expressed on a cell surface or on a solid support.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cell is a JIMT-1 cell.

### Claim 6 (depends on 4)

The method of claim 4, wherein the solid support is a biosensor.

### Claim 7 (depends on 1)

The method of claim 1, wherein the first antibody or antigen binding fragment thereof comprises:
a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence at least 80% identical thereto, and a variable light chain comprising the amino acid sequence of SEQ ID NO: 14, or an amino acid sequence at least 80% identical thereto;
a heavy chain comprising the amino acid sequence of SEQ ID NO: 5, or an amino acid sequence at least 80% identical thereto, and a light chain comprising the amino acid sequence of SEQ ID NO: 6, or an amino acid sequence at least 80% identical thereto;
wherein the antibody or antigen binding fragment bind the HER2 receptor.

### Claim 8 (depends on 1)

The method of claim 1, wherein the second antibody or antigen binding fragment is obtained by screening a library comprising antibody or antigen binding domain sequences expressed in display type technologies including phage display, retroviral display, or ribosomal display.

### Claim 9 (depends on 8)

The method of claim 8, wherein the bacteriophage displayed library comprises phage carrying randomized pairs of light and heavy chains.

### Claim 10 (depends on 8)

The method of claim 8, wherein the second antibody or antigen binding fragment thereof that competes for specific binding to a human HER2 receptor is identified by an in vitro assay comprising enzyme linked immunosorbent assay (ELISA), western blot, immunoprecipitation, or immunofluorescence.

### Claim 11 (depends on 1)

The isolated antibody or antigen binding fragment thereof of claim 1, wherein the antibody or antigen binding fragment thereof is a monoclonal antibody, a domain antibody, a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a single chain variable fragment (scFv), a scFv-Fc fragment, a single chain antibody (scAb), a domain antibody (dAb), a single domain heavy chain antibody, or a single domain light chain antibody.

### Claim 12 (depends on 1)

The method of claim 1, wherein the isolated antibody or antigen binding fragment thereof is a rabbit, mouse, chimeric, humanized or fully human monoclonal antibody.

### Claim 13 (depends on 1)

The method of claim 1, wherein the isolated antibody or antigen binding fragment thereof is an IgG isotype.

### Claim 14 (depends on 1)

The method of claim 1, wherein the isolated antibody or antigen binding fragment thereof is an IgG1 isotype.
